Was documented for 827 of these tumours. Grades wereFGFR3 and TP53 Mutations in Bladder Cancerprovided in the study by Lamy et al., but it was impossible to retrieve information about both stage and grade for a given tumour [15]. We therefore excluded the data from the study by Lamy et al. from the combined investigation of stage and grade. The stages and grades of tumours for each study are summarised in Tables S1 and S2 (published studies) and Table S3 (unpublished studies). In total, there were 350 pTa, 1676428 358 pT1, 209 pT2-4 and 88 G1, 249 G2 and 490 G3 tumours. For the combined analysis of stage and grade, we ��-Sitosterol ��-D-glucoside site considered the following five categories of tumours: pTaG1 plus pTaG2 (as a 
single category), pTaG3, pT1G2, pT1G3 and pT2-4 tumours. We classified pTaG1 and pTaG2 tumours together, and pT2, pT3 and pT4 tumours together as, in each of these groups, the tumours concerned are considered to constitute the same clinical entity, regardless of grade.in pT1, 50.7 in pT2-4, and 3.8 in G1, 12.05 in G2 and 46.3 in G3. These trends, for both stage and grade, were highly significant (p,0.0001 and p,0.0001 respectively), suggesting that stage and grade may be confounding factors.Association between FGFR3 and TP53 mutations, adjusting for stage or for gradeWe then studied mutation status for both FGFR3 and TP53, as a function of stage (Figure 2). For pTa tumours, the 25837696 most common of the four possible groups (wild-type FGFR3 plus wild-type TP53, wild-type FGFR3 plus mutated TP53, mutated FGFR3 plus wildtype TP53, mutated FGFR3 plus mutated TP53) was tumours with mutated FGFR3 and wild-type TP53 (208/336; 61.9 of cases), followed by tumours wild-type for both FGFR3 and TP53 (106/ 336; 31.5 of cases). A small number of tumours had TP53 mutations and were either wild-type for FGFR3 (11/336; 3.3 ) or mutated for FGFR3 (11/336; 3.3 ). For pT1 tumours, the two most common groups were tumours wild-type for both FGFR3 and TP53 (134/355; 37.7 of cases) or wild-type for FGFR3 and mutated 
for TP53 (115/355; 32.4 of cases). For invasive tumours (pT2-4), the two most common groups were also tumours wildtype for both FGFR3 and TP53 (88/207; 42.5 of cases) or wildtype for FGFR3 and mutated for TP53 (95/207; 45.9 of cases). We then investigated whether FGFR3 and TP53 mutations were independent events. We defined four groups (wild-type FGFR3 plus wild-type TP53, wild-type FGFR3 plus mutated TP53, mutated FGFR3 plus wild-type TP53, mutated FGFR3 plus mutated TP53). We carried out a Mantel-Haenszel test, stratified for stage, to determine whether the proportion of tumours withDistribution of FGFR3 and TP53 mutations by stage and by gradeFGFR3 mutation status was available for 916 of the 917 tumours with a documented stage and TP53 mutation status was available for 898 of the 917 tumours. This meta-analysis, like many previous studies, showed an inverse relationship between FGFR3 and TP53 mutations for both stage and grade (Figure 1). The frequency of FGFR3 mutations AN 3199 biological activity decreased with increasing stage and grade: 65 in pTa, 30.2 in pT1, 11.5 in pT2-4 and 69.8 in G1, a very similar rate in G2 (68 ) and 18.6 in G3. These trends, for both stage and grade, were highly significant (p,0.0001 and p,0.0001, respectively). By contrast, the frequency of TP53 mutations increased with increasing stage and grade: 6.55 in pTa, 40.6Figure 1. FGFR3 and TP53 mutation frequencies by stage (pT) or grade (G). Proportion of wild-type tumours and of tumours with FGFR3 (upper r.Was documented for 827 of these tumours. Grades wereFGFR3 and TP53 Mutations in Bladder Cancerprovided in the study by Lamy et al., but it was impossible to retrieve information about both stage and grade for a given tumour [15]. We therefore excluded the data from the study by Lamy et al. from the combined investigation of stage and grade. The stages and grades of tumours for each study are summarised in Tables S1 and S2 (published studies) and Table S3 (unpublished studies). In total, there were 350 pTa, 1676428 358 pT1, 209 pT2-4 and 88 G1, 249 G2 and 490 G3 tumours. For the combined analysis of stage and grade, we considered the following five categories of tumours: pTaG1 plus pTaG2 (as a single category), pTaG3, pT1G2, pT1G3 and pT2-4 tumours. We classified pTaG1 and pTaG2 tumours together, and pT2, pT3 and pT4 tumours together as, in each of these groups, the tumours concerned are considered to constitute the same clinical entity, regardless of grade.in pT1, 50.7 in pT2-4, and 3.8 in G1, 12.05 in G2 and 46.3 in G3. These trends, for both stage and grade, were highly significant (p,0.0001 and p,0.0001 respectively), suggesting that stage and grade may be confounding factors.Association between FGFR3 and TP53 mutations, adjusting for stage or for gradeWe then studied mutation status for both FGFR3 and TP53, as a function of stage (Figure 2). For pTa tumours, the 25837696 most common of the four possible groups (wild-type FGFR3 plus wild-type TP53, wild-type FGFR3 plus mutated TP53, mutated FGFR3 plus wildtype TP53, mutated FGFR3 plus mutated TP53) was tumours with mutated FGFR3 and wild-type TP53 (208/336; 61.9 of cases), followed by tumours wild-type for both FGFR3 and TP53 (106/ 336; 31.5 of cases). A small number of tumours had TP53 mutations and were either wild-type for FGFR3 (11/336; 3.3 ) or mutated for FGFR3 (11/336; 3.3 ). For pT1 tumours, the two most common groups were tumours wild-type for both FGFR3 and TP53 (134/355; 37.7 of cases) or wild-type for FGFR3 and mutated for TP53 (115/355; 32.4 of cases). For invasive tumours (pT2-4), the two most common groups were also tumours wildtype for both FGFR3 and TP53 (88/207; 42.5 of cases) or wildtype for FGFR3 and mutated for TP53 (95/207; 45.9 of cases). We then investigated whether FGFR3 and TP53 mutations were independent events. We defined four groups (wild-type FGFR3 plus wild-type TP53, wild-type FGFR3 plus mutated TP53, mutated FGFR3 plus wild-type TP53, mutated FGFR3 plus mutated TP53). We carried out a Mantel-Haenszel test, stratified for stage, to determine whether the proportion of tumours withDistribution of FGFR3 and TP53 mutations by stage and by gradeFGFR3 mutation status was available for 916 of the 917 tumours with a documented stage and TP53 mutation status was available for 898 of the 917 tumours. This meta-analysis, like many previous studies, showed an inverse relationship between FGFR3 and TP53 mutations for both stage and grade (Figure 1). The frequency of FGFR3 mutations decreased with increasing stage and grade: 65 in pTa, 30.2 in pT1, 11.5 in pT2-4 and 69.8 in G1, a very similar rate in G2 (68 ) and 18.6 in G3. These trends, for both stage and grade, were highly significant (p,0.0001 and p,0.0001, respectively). By contrast, the frequency of TP53 mutations increased with increasing stage and grade: 6.55 in pTa, 40.6Figure 1. FGFR3 and TP53 mutation frequencies by stage (pT) or grade (G). Proportion of wild-type tumours and of tumours with FGFR3 (upper r.
